Immunic Inc
NASDAQ:IMUX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corning Inc
XETRA:GLW
|
US |
|
Pansoft Co Ltd
SZSE:300996
|
CN |
|
M
|
Mountview Estates PLC
LSE:MTVW
|
UK |
|
China Foods Ltd
HKEX:506
|
HK |
|
Shenzhen Noposion Agrochemicals Co Ltd
SZSE:002215
|
CN |
|
T
|
Triveni Glass Ltd
BSE:502281
|
IN |
|
A
|
Allianz Malaysia Bhd
KLSE:ALLIANZ
|
MY |
|
Alamo Group Inc
NYSE:ALG
|
US |
|
Gree Electric Appliances Inc of Zhuhai
SZSE:000651
|
CN |
Immunic Inc
EPS (Diluted)
Immunic Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunic Inc
NASDAQ:IMUX
|
EPS (Diluted)
$0
|
CAGR 3-Years
45%
|
CAGR 5-Years
26%
|
CAGR 10-Years
39%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
EPS (Diluted)
-€4
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
EPS (Diluted)
-€1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
EPS (Diluted)
€0
|
CAGR 3-Years
24%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
EPS (Diluted)
-€7
|
CAGR 3-Years
-81%
|
CAGR 5-Years
-99%
|
CAGR 10-Years
N/A
|
|
Immunic Inc
Glance View
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 55 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The firm is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
See Also
What is Immunic Inc's EPS (Diluted)?
EPS (Diluted)
-0.6
USD
Based on the financial report for Dec 31, 2025, Immunic Inc's EPS (Diluted) amounts to -0.6 USD.
What is Immunic Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
39%
Over the last year, the EPS (Diluted) growth was 38%. The average annual EPS (Diluted) growth rates for Immunic Inc have been 45% over the past three years , 26% over the past five years , and 39% over the past ten years .
